Kelzyn

Dienogest, the active ingredient in Kelzyn, is a combined oral contraceptive presented as a tablet for oral use. It works together with ethinylestradiol to prevent pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus during the menstrual cycle.

GNH USA supplies Kelzyn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide, ensuring consistent quality and regulatory compliance across markets through robust supply chain management and validated manufacturing processes.

Kelzyn, a combined oral contraceptive, is used to prevent pregnancy by modulating the hormonal axis.

- Prevention of pregnancy: provides reliable hormonal contraception for women of child‑bearing potential. - Regulation of menstrual cycles: helps achieve more predictable bleeding patterns and reduces menstrual discomfort. - Treatment of moderate acne: may improve skin condition by decreasing androgenic activity in some women.

Kelzyn may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: occasional throbbing or tension‑type pain. - Spotting or breakthrough bleeding: irregular light bleeding between periods. - Mood changes: irritability or mild mood swings. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Arterial thrombosis: clot formation in arteries, potentially leading to stroke or heart attack. - Severe hypertension: sudden rise in blood pressure. - Liver dysfunction: abnormal liver enzymes or jaundice. - Anaphylaxis: rare severe allergic reaction. - Visual disturbances: sudden changes in vision or eye pain.

Before prescribing Kelzyn, clinicians should evaluate individual risk factors and counsel patients on safe use.

- Cardiovascular assessment: review history of thromboembolic events or clotting disorders. - Smoking status: avoid use in women over 35 who smoke. - Liver function: assess hepatic disease before initiation. - Pregnancy screening: confirm patient is not pregnant before starting therapy. - Contraindications: do not use in known thrombophilia, breast cancer, or uncontrolled hypertension. - Drug interactions: review concomitant medications that may affect efficacy. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Kelzyn can interact with several medicines, altering its contraceptive effectiveness or increasing adverse risk.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): markedly reduce hormonal levels. - Rifampin and other strong CYP3A4 inducers: may cause contraceptive failure. - St. John's wort: herbal inducer that lowers estrogen exposure.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly reduce effectiveness. - Antifungal agents (e.g., ketoconazole, itraconazole): can increase hormone concentrations. - Protease inhibitors and some antiretrovirals: may require additional non‑hormonal contraception.